8:45 am Morning Coffee & Networking

9:25 am Chair’s Opening Remarks

Overcoming Operational Challenges to Empower Data Analysis Efforts

9:30 am Fireside Chat: Best Practices in Spatial Omics Data Generation & Analytics to Empower Drug Development Across Disease Areas

Synopsis

  • Exploring best practices and troubleshooting strategies to effectively leverage spatial technologies to enhance biomarker discovery
  • Examining diverse applications of spatial omics to support research across oncology, inflammation, neurological disorders, and other disease areas
  • Harnessing spatial and multi-omics datasets through AI and machine learning tools to derive superior insights in target identification and patient stratification

Moderated by Angela Hadjipanayis, Head of Disease Profiling Genomics & Flow Cytometry, PMCB, Sanofi

10:15 am Proteomap: A Discovery-Focused Multiplexed Imaging Approach

  • Shoh Asano Senior Principal Scientist Microscopy and Image Analysis, Pfizer

Synopsis

  • Multiplexed imaging approaches are ideal to probe for multiple markers on the same tissue to support target ID and validation in the exploratory space
  • Proteomap is a flexible, affordable and universal multiplexed imaging method that has been utilized on many tissue types across species
  • Examples will demonstrate how this technology is utilized to address and refine common research questions within the drug discovery process

10:45 am Morning Break

Leveraging Computational Tools to Support Targeted Drug Development

11:30 am Building a Machine Learning Model on Spatial Transcriptomic Data to Support Targeted Immuno-Oncology Drug Development

Synopsis

  • Uncovering strategies to train a machine learning model on limited high-cost Xenium data to enhance drug development
  • Applying this model to H&E data to annotate cell types and observe patterns, maximizing the utility of currently available datasets
  • Investigating the spatial patterns in these annotated images to identify potential correlations between spatial distributions of cells and clinical prognosis, offering new insights into disease progression and outcomes

12:00 pm Optimizing Imaging Acquisition Techniques to Gain Better Insights From Your Data to Inform Oncology Drug Development

Synopsis

  • Applying spatial biology to understand drug mechanisms of action and efficacy, with multi-tiered analysis from cell density quantification to cell interaction dynamics within the tumor microenvironment
  • Utilizing these tools to identify biomarkers that can predict patient outcomes, enhancing treatment approaches
  • Focusing on improving imaging acquisition techniques to obtain higher quality data, leading to more precise biomarker development and insightful analysis in spatial biology studies

12:30 pm Lunch Break & Networking

Applications of Spatial Biology to Empower Better Image Analysis & Assessing the Future of the Field

1:30 pm Fireside chat: Mapping Out the Future of Spatial Biology in Biopharma

  • Komal Sane Regulatory Affairs, Regeneron
  • Eugean Jiwanmall Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross
  • Pahini Pandya Chief Executive Officer & Co-Founder, Panakeia Technologies

Synopsis

  • Re-iterating the importance of cross-collaboration and knowledge transfer between biopharma, academics, vendors, regulators and other key stakeholders
  • Evaluating the growing question: can we use spatial data to support clinical trials at scale
  • Discussing the immediate next steps the field needs to take to overcome barriers

2:15 pm Afternoon Break & Networking

Uncovering the Latest Applications of Single-Cell Technology & Understanding the Next Steps for Spatial Biology in Clinical Use

2:45 pm A Payor’s Perspective on Spatial Biology: Evidence Requirements for Novel Technologies

  • Eugean Jiwanmall Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross

Synopsis

  • Understanding the evidence requirements and approval criteria for novel technologies in drug development, with a focus on the U.S. regulatory environment
  • Identifying the current state of research, future directions, and key emphasis areas for demonstrating drug efficacy, including addressing unmet clinical needs and assessing alternatives
  • Guiding R&D and commercialization efforts by highlighting critical clinical questions, necessary outcomes, and criteria for demonstrating clinical equivalence or superiority to ensure successful acceptance for reimbursement

3:15 pm Spotlighting Lessons Learned from Adopting & Leveraging Deep Visual Proteomics in Translational Research

Synopsis

  • Exploring best practices and troubleshooting strategies to effectively leverage deep visual proteomics across drug development
  • Uncovering the different applications of this tool across multiple tissue types to gain better throughput
  • Sharing the future applications and hopes for this technology to gain better disease insights

3:45 pm Chair’s Closing Remarks & End of Summit